JASCAYD

At a glance

Key dates

1. Approval

   FDA approval date of this drug product.

   Oct 07, 2025

   9 mo ago

2. Today

3. Exclusivity ends · I-979

   New indication exclusivity (3 years)

   Dec 19, 2028

   in 2 yr 6 mo

4. Patent 8754073 expires

   Listed drug substance patent expiration.

   Nov 26, 2029

   in 3 yr 6 mo

5. Exclusivity ends · NCE

   New chemical entity exclusivity (5 years)

   Oct 07, 2030

   in 4 yr 4 mo

6. Patent 8609670 expires

   Listed drug substance patent expiration.

   Aug 23, 2032

   in 6 yr 3 mo

7. Exclusivity ends · ODE-546

   Orphan-drug exclusivity (7 years)

   Oct 07, 2032

   in 6 yr 5 mo

8. Patent 9802954 expires

   Listed method-of-use patent (U-4298) expiration.

   Feb 19, 2034

   in 7 yr 9 mo

9. Patent 11406638 expires

   Listed method-of-use patent (U-4373) expiration.

   Oct 22, 2038

   in 12 yr 6 mo

10. Patent 11406638 expires

    Listed method-of-use patent (U-4297) expiration.

    Oct 22, 2038

    in 12 yr 6 mo

11. Patent 11813266 expires

    Listed method-of-use patent (U-4372) expiration.

    Oct 22, 2038

    in 12 yr 6 mo

12. Patent 11813266 expires

    Listed method-of-use patent (U-4292) expiration.

    Oct 22, 2038

    in 12 yr 6 mo

Pharmaceutical detail

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Marketing exclusivity (3)

• I-979New indication exclusivity (3 years)

  Dec 19, 2028

  in 2 yr 6 mo

• NCENew chemical entity exclusivity (5 years)

  Oct 07, 2030

  in 4 yr 4 mo

• ODE-546Orphan-drug exclusivity (7 years)

  Oct 07, 2032

  in 6 yr 5 mo

Listed patents (7)